Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients

详细信息    查看全文

• 作者：Kihyun Kim (1)
  Seok Jin Kim (1)
  Verena Voelter (2)
  Cheolwon Suh (3)
  Sung-Soo Yoon (4)
  Je-Jung Lee (5)
  Jae-Yong Kwak (6)
  Hun-Mo Ryoo (7)
  Yang Soo Kim (8)
  Joon Ho Moon (9)
  Seong Kyu Park (10)
  Sung-Hyun Kim (11)
  Yeung-Chul Mun (12)
  Jin Seok Kim (13)
  Hyeon-Seok Eom (14)
  Deog-Yeon Jo (15)
  Hyun Jung Jun (16)
  Ki-Hwan Kim (17)
  Jeong-Ok Lee (18)
  Jae Hoon Lee (19)
  Chang-Ki Min (20)
  
• 关键词：Lenalidomide ; Relapsed myeloma ; Korean
• 刊名：Annals of Hematology
• 出版年：2014
• 出版时间：January 2014
• 年：2014
• 卷：93
• 期：1
• 页码：113-121
• 全文大小：201 KB
• 作者单位：Kihyun Kim (1)
  Seok Jin Kim (1)
  Verena Voelter (2)
  Cheolwon Suh (3)
  Sung-Soo Yoon (4)
  Je-Jung Lee (5)
  Jae-Yong Kwak (6)
  Hun-Mo Ryoo (7)
  Yang Soo Kim (8)
  Joon Ho Moon (9)
  Seong Kyu Park (10)
  Sung-Hyun Kim (11)
  Yeung-Chul Mun (12)
  Jin Seok Kim (13)
  Hyeon-Seok Eom (14)
  Deog-Yeon Jo (15)
  Hyun Jung Jun (16)
  Ki-Hwan Kim (17)
  Jeong-Ok Lee (18)
  Jae Hoon Lee (19)
  Chang-Ki Min (20)
  
  1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, South Korea
  2. Celgene Korea, Seoul, South Korea
  3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  4. Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
  5. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea
  6. Department of Internal Medicine, Chonbuk National University Medical School, Jeonju, South Korea
  7. Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea
  8. Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea
  9. Department of Internal Medicine, Kyungpook National University Hospital, Daegu, South Korea
  10. Department of Internal medicine, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea
  11. Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea
  12. Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, South Korea
  13. Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
  14. Hematology-Oncology Clinic, National Cancer Center, Goyang-si, South Korea
  15. Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, South Korea
  16. Medical Oncology and Hematology, Department of Internal Medicine, Seoul Medical Center, Seoul, South Korea
  17. Department of Internal Medicine, Seoul National University Boramae Hospital, Seoul, South Korea
  18. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea
  19. Department of Internal Medicine, Gachon University Gil Hospital, Incheon, South Korea
  20. Division of Hematology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 505 Banpo-Dong, Seocho-Gu, Seoul, 137-701, South Korea
  
• ISSN：1432-0584

文摘

We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6?% with 15.4?% of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0?months, and median overall survival (OS) was 23?months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.